Eli Lilly and Company
LLY
$1064.15
-1.67%
Eli Lilly and Company is a global pharmaceutical leader focused on discovering, developing, and marketing medicines across key therapeutic areas including cardiometabolic health, immunology, neuroscience, and oncology. The company is a dominant market leader, particularly distinguished by its blockbuster GLP-1 drugs for diabetes and obesity, which have established it as a premier growth name in the large-cap biopharma sector. The current investor narrative is overwhelmingly centered on the company's execution and expansion within the massive obesity/diabetes market, with recent headlines highlighting breakthrough efficacy data for its next-generation drug retatrutide and strategic acquisitions to build out its infectious disease and vaccine portfolio, fueling debates about sustainable growth versus its already premium valuation.…
LLY
Eli Lilly and Company
$1064.15
Related headlines
Investment Opinion: Should I buy LLY Today?
Rating: Hold. The core thesis is that Eli Lilly's exceptional fundamental execution is fully, if not overly, reflected in its premium valuation, creating a balanced risk/reward profile at current levels. The Hold rating is supported by four key data points: 1) explosive 42.6% YoY revenue growth justifying a growth premium, 2) a high but declining forward PE of 24.85x (from a trailing 46.76x), implying earnings are catching up to the price, 3) robust analyst sentiment with an average revenue estimate of $130.61B for the next period, and 4) superior profitability metrics like a 77.78% ROE and 34.4% net margin that are best-in-class. However, the Price-to-Sales of 14.81x is exceptionally high, indicating much future success is already priced in. The thesis would upgrade to a Buy if the forward PE compresses below 20x on market weakness without a deterioration in the growth outlook, or if next-generation pipeline drugs like retatrutide show even larger market opportunities. It would downgrade to a Sell if quarterly revenue growth decelerates below 30% or if net margins contract sequentially. Relative to its own history and pharma peers, the stock is overvalued on absolute multiples but may be fairly valued if its transformative growth rate is sustained for several more years.
Sign up to view all
LLY 12-Month Price Forecast
The outlook is balanced with a slight skew to the base case. The company's fundamental momentum is undeniable, but the valuation leaves little room for error. The key will be whether Q3 and Q4 2026 earnings can demonstrate that 40%+ growth is sustainable, which would support the current multiple. The stance would upgrade to bullish on evidence of sustained margin expansion and successful pipeline diversification beyond GLP-1s. It would turn bearish on any concrete signs of market share loss or growth deceleration below 25%. The wide analyst EPS range underscores the high execution risk embedded in the price.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Eli Lilly and Company's 12-month outlook, with a consensus price target around $1383.40 and implied upside of +30.0% versus the current price.
Average Target
$1383.40
11 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
11
covering this stock
Price Range
$851 - $1383
Analyst target range
Analyst coverage is robust with 11 firms providing estimates, indicating strong institutional interest. The consensus sentiment is overwhelmingly bullish, as evidenced by the recent institutional ratings which include multiple 'Overweight' and 'Buy' reiterations from major firms like JP Morgan, Morgan Stanley, and Deutsche Bank in February 2026, though a lone 'Reduce' from HSBC in March signals some valuation concerns. The average revenue estimate for the next period is $130.61 billion, with a wide range from $122.65B to $139.84B, reflecting uncertainty around the exact trajectory of new drug launches. The target price range implied by earnings estimates is wide, signaling high uncertainty around future earnings power. The high EPS estimate of $68.68 assumes flawless commercial execution, rapid market share gains, and successful pipeline conversions, potentially justifying further multiple expansion. The low EPS estimate of $57.92 likely factors in risks like increased competition, pricing pressure, or slower-than-expected market penetration. The tight clustering of most recent analyst actions around 'Buy' or 'Overweight' suggests the bullish narrative remains intact, but the wide EPS range underscores the significant operational and competitive execution risk embedded in the current premium valuation.
Bulls vs Bears: LLY Investment Factors
The bull case, driven by explosive 42.6% revenue growth, expanding 34.4% net margins, and a dominant clinical pipeline, currently holds stronger evidence given the fundamental execution. However, the bear case centered on a precarious premium valuation is equally compelling, creating the central tension of the investment debate. The single most important factor is whether Lilly can sustain its current hyper-growth trajectory to justify its forward PE of 24.85x, or if growth normalizes, leading to a painful derating. The stock's recent volatility reflects this binary outcome between continued market dominance and valuation mean reversion.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue grew 42.6% YoY to $19.29B, driven by the blockbuster launch of Mounjaro and Zepbound. This acceleration from prior quarters demonstrates the powerful commercial trajectory of the GLP-1 franchise.
- Exceptional Profitability & Margins: Net margin expanded to 34.4% in Q4 2025, with a gross margin of 85.05% and operating margin of 45.5%. This showcases significant operating leverage and premium pricing power for its innovative drugs.
- Dominant Pipeline & Clinical Success: Recent news highlights breakthrough efficacy for next-generation drug retatrutide, solidifying Lilly's lead in the massive obesity market. This supports long-term growth beyond current blockbusters.
- Strong Cash Generation & ROE: The company generated $8.97B in TTM free cash flow and boasts an extraordinary Return on Equity of 77.78%. This provides ample internal funding for R&D, dividends, and strategic acquisitions.
Bearish
- Premium Valuation at Risk: The forward PE of 24.85x and Price-to-Sales of 14.81x are at a substantial premium to typical large-cap pharma. Any growth deceleration or negative clinical news could trigger severe multiple compression.
- Revenue Concentration Risk: The Cardiometabolic Health segment generated $13.18B in Q4 2025, constituting the vast majority of sales. The company's fortunes are heavily tied to the success and pricing of its GLP-1 drugs, creating single-product dependency.
- High Leverage for Growth: A debt-to-equity ratio of 1.60 reflects a leveraged capital structure to fund aggressive R&D and acquisitions. While manageable, it increases financial risk if growth unexpectedly slows.
- Technical Volatility & Correction: The stock is at 84% of its 52-week range after a sharp pullback from its $1,149.10 high, with a 3-month return of +5.04% underperforming the S&P 500's +10.28%. This indicates investor caution and potential trend exhaustion.
LLY Technical Analysis
The stock is in a sustained long-term uptrend but has experienced significant volatility and a sharp correction recently. The 1-year price change of +52.93% confirms a powerful bullish trend, yet the current price of $1,105 sits at approximately 84% of its 52-week range ($623.78 to $1,149.10), indicating it has retreated meaningfully from its highs after a period of overextension. This positioning suggests the stock is consolidating after a parabolic move, offering a potential entry point for trend followers but also reflecting heightened investor caution near record levels. Recent momentum shows a dramatic short-term surge conflicting with intermediate-term weakness, signaling a potential trend reversal or volatile consolidation. The 1-month price change is a massive +29.82%, sharply outperforming the S&P 500's +6.31% and indicating explosive recent buying pressure. However, the 3-month change is only +5.04%, which underperforms the market's +10.28% and diverges negatively from the 1-year trend, suggesting the stock was in a significant downtrend from March to April before the late-May rally. This divergence highlights extreme volatility, likely driven by binary news flow around clinical trial results. Key technical levels are clearly defined by the 52-week high of $1,149.10 as immediate resistance and the 52-week low of $623.78 as major support. A decisive breakout above the $1,150 resistance would signal a resumption of the primary bull trend and could target new highs, while a breakdown below the recent March low near $878 would indicate a deeper correction is underway. The stock's beta of 0.48 indicates it has been significantly less volatile than the broader market over the measured period, which is unusual for a growth biopharma name and may reflect its mega-cap status and defensive characteristics during the recent pullback, though the price data shows it has experienced high absolute volatility.
Beta
0.48
0.48x market volatility
Max Drawdown
-30.4%
Largest decline past year
52-Week Range
$624-$1149
Price range past year
Annual Return
+42.4%
Cumulative gain past year
| Period | LLY Return | S&P 500 |
|---|---|---|
| 1m | +10.5% | +5.4% |
| 3m | +6.0% | +10.9% |
| 6m | +4.9% | +11.0% |
| 1y | +42.4% | +28.1% |
| ytd | -1.5% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LLY Fundamental Analysis
Revenue growth is exceptionally strong and accelerating, driven overwhelmingly by the company's cardiometabolic franchise. Q4 2025 revenue reached $19.29 billion, representing a massive 42.6% year-over-year growth. This growth rate has accelerated sequentially from prior quarters, with Q3 2025 revenue at $17.60 billion (up from $11.44B in Q3 2024) and Q2 2025 at $15.56 billion (up from $11.30B in Q2 2024), demonstrating the powerful launch trajectory of Mounjaro and Zepbound. Segment data confirms the Cardiometabolic Health segment generated $13.18 billion, constituting the vast majority of sales and serving as the primary growth engine. Profitability is robust and margins are expanding significantly, reflecting operating leverage from soaring sales. Net income for Q4 2025 was $6.64 billion, yielding a net margin of 34.4%. The gross margin of 85.05% is exceptionally high and consistent with prior quarters (82.9% in Q3), indicative of the premium pricing power of its innovative drugs. Operating income of $8.78 billion resulted in an operating margin of 45.5%, showcasing impressive scalability as revenue growth far outpaces the increase in R&D and SG&A expenses. The balance sheet is strong with substantial cash generation, though leverage has increased to fund growth initiatives. The company generated $8.97 billion in trailing twelve-month free cash flow, providing ample internal funding for R&D, dividends, and acquisitions. The debt-to-equity ratio of 1.60 reflects a leveraged but manageable capital structure, typical for a pharma company investing heavily in its pipeline. Return on Equity is extraordinarily high at 77.78%, underscoring the immense profitability and efficient use of shareholder capital, while the current ratio of 1.58 indicates comfortable short-term liquidity.
Quarterly Revenue
$19.3B
2025-12
Revenue YoY Growth
+0.42%
YoY Comparison
Gross Margin
+0.85%
Latest Quarter
Free Cash Flow
$9.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LLY Overvalued?
Given the substantial positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 46.76x, while the forward PE is 24.85x based on estimated EPS. The significant gap between trailing and forward multiples implies the market is pricing in a near-doubling of earnings, reflecting high confidence in continued explosive bottom-line growth driven by the obesity drug franchise. Compared to the broader Drug Manufacturers industry, Eli Lilly trades at a substantial premium. The forward PE of 24.85x is well above typical large-cap pharma averages (often in the mid-teens), and the Price-to-Sales ratio of 14.81x is also elevated. This premium is directly justified by the company's superior growth profile; the 42.6% YoY revenue growth and expanding 34.4% net margin are far ahead of industry norms, warranting a higher multiple for what is perceived as a transformative growth story within a traditionally stable sector. Historically, the current trailing PE of 46.76x is near the upper end of its own range over the past several years, as seen in historical ratios where it has fluctuated from the 30s to over 200x during periods of investment or low earnings. Trading near historical highs suggests the market has already priced in a near-perfect execution scenario for its growth drugs. Any stumble in growth acceleration or margin expansion could lead to significant multiple contraction, while sustained execution could support these elevated levels.
PE
46.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -2221x~206x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
35.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are moderated by stellar profitability but heightened by concentration and leverage. The 34.4% net margin and $8.97B in FCF provide a robust cushion, yet over 68% of Q4 revenue came from the Cardiometabolic segment, creating acute dependency on GLP-1 drug success. The debt-to-equity ratio of 1.60, while typical for aggressive pharma growth, means interest expense and refinancing risk become material if the growth engine sputters. Any stumble in the obesity drug launch trajectory could simultaneously hit revenue growth and operating leverage, pressuring the elevated margins. Market and competitive risks are severe, primarily centered on valuation compression. Trading at a forward PE of 24.85x—a significant premium to large-cap pharma peers—the stock is priced for near-perfect execution. Intensifying competition from Novo Nordisk, potential payer pushback on high drug prices, and regulatory scrutiny pose direct threats to the growth narrative that justifies this multiple. The stock's low beta of 0.48 is deceptive given its recent high absolute volatility; it remains highly sensitive to binary clinical news and analyst sentiment shifts, as seen in the wide analyst EPS range from $57.92 to $68.68. The worst-case scenario involves a combination of clinical setbacks, accelerated competitive launches, and pricing pressure leading to a growth deceleration. This could trigger a cascade of analyst downgrades and multiple contraction towards historical pharma averages. A realistic downside could see the stock re-test its recent March low of ~$878, representing a -21% decline from the current $1,105. In a more severe bear case aligning with the 52-week low of $623.78, losses could exceed -44%, though this would require a fundamental breakdown in the core franchise, which current execution does not suggest is imminent.
FAQ
The key risks are, in order of severity: 1) Valuation Risk: A high forward PE of 24.85x makes the stock vulnerable to multiple compression if growth slows. 2) Product Concentration Risk: Over 68% of Q4 revenue came from the Cardiometabolic segment, creating dependency on GLP-1 drugs. 3) Competitive Risk: Intense rivalry with Novo Nordisk could erode market share and pricing power. 4) Financial Risk: A debt-to-equity ratio of 1.60, while manageable, increases leverage in a rising rate environment. 5) Execution Risk: The wide analyst EPS range ($57.92-$68.68) highlights uncertainty around the precise growth trajectory.
The 12-month forecast presents three scenarios. The Base Case (50% probability) targets $1,050-$1,200, assuming robust but moderating growth supports the current valuation. The Bull Case (30% probability) targets $1,250-$1,400, driven by flawless execution and pipeline successes. The Bear Case (20% probability) targets $850-$950, triggered by growth deceleration and multiple contraction. The Base Case is most likely, anchored by the analyst average earnings estimate of $62.90. The key assumption is that revenue growth remains above 25%, preventing a severe derating of the stock.
Based on traditional metrics, LLY is overvalued relative to its pharmaceutical industry peers, trading at a forward PE of 24.85x and a Price-to-Sales ratio of 14.81x, well above sector averages. However, this premium is directly tied to its extraordinary growth profile, with 42.6% YoY revenue growth and 34.4% net margins that are unmatched in large-cap pharma. The valuation implies the market expects this hyper-growth to continue for several years. Therefore, it is fairly valued only if the company meets these lofty growth expectations; it is overvalued if growth normalizes sooner than anticipated.
LLY is a high-quality stock with exceptional fundamentals, but its attractiveness as a buy depends heavily on an investor's risk tolerance and time horizon. At a forward PE of 24.85x, much of the future growth is already priced in, offering limited margin of safety. The stock could be a good buy for long-term growth investors willing to accept volatility and who believe the obesity drug market will expand beyond current expectations. However, for value-conscious or risk-averse investors, the current premium valuation and concentration risk make it a less compelling immediate purchase, suggesting a 'Hold' and wait for a better entry point during market pullbacks.
LLY is primarily suitable for long-term investment (3-5 year minimum horizon). Its low beta of 0.48 and mega-cap status provide some stability, but its recent price volatility and premium valuation make it a risky short-term trade. The investment thesis is based on the multi-year expansion of the obesity drug market and pipeline conversion, which are long-duration stories. The minimal dividend yield (0.56%) also means total return is dependent on price appreciation. Short-term traders face high volatility driven by binary clinical news and earnings reports, as evidenced by the 1-month surge of +29.82% followed by periods of sharp correction.
